

Hartej Gill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4104439/publications.pdf>

Version: 2024-02-01

44
papers

5,531
citations

304368

22
h-index

243296

44
g-index

44
all docs

44
docs citations

44
times ranked

6484
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of COVID-19 pandemic on mental health in the general population: A systematic review. <i>Journal of Affective Disorders</i> , 2020, 277, 55-64.	2.0	3,399
2	Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. <i>Brain, Behavior, and Immunity</i> , 2022, 101, 93-135.	2.0	670
3	Government response moderates the mental health impact of COVID-19: A systematic review and meta-analysis of depression outcomes across countries. <i>Journal of Affective Disorders</i> , 2021, 290, 364-377.	2.0	159
4	The Effect of Loneliness on Distinct Health Outcomes: A Comprehensive Review and Meta-Analysis. <i>Psychiatry Research</i> , 2020, 294, 113514.	1.7	156
5	The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. <i>Journal of Affective Disorders</i> , 2020, 276, 576-584.	2.0	118
6	The long-term effect of bariatric surgery on depression and anxiety. <i>Journal of Affective Disorders</i> , 2019, 246, 886-894.	2.0	117
7	The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Affective Disorders</i> , 2020, 274, 903-910.	2.0	70
8	Antidepressant Medications and Weight Change: A Narrative Review. <i>Obesity</i> , 2020, 28, 2064-2072.	1.5	62
9	The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2021, 134, 57-68.	1.5	58
10	The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 120, 78-85.	2.9	48
11	Registered clinical studies investigating psychedelic drugs for psychiatric disorders. <i>Journal of Psychiatric Research</i> , 2021, 139, 71-81.	1.5	47
12	Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. <i>CNS Drugs</i> , 2022, 36, 17-30.	2.7	45
13	Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research. <i>Infectious Diseases</i> , 2022, 54, 467-477.	1.4	42
14	The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. <i>Bipolar Disorders</i> , 2020, 22, 831-840.	1.1	40
15	A Systematic review of the validity of screening depression through Facebook, Twitter, Instagram, and Snapchat. <i>Journal of Affective Disorders</i> , 2021, 286, 360-369.	2.0	36
16	Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders. <i>CNS Drugs</i> , 2021, 35, 925-934.	2.7	35
17	Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2022, 300, 449-461.	2.0	34
18	Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Affective Disorders</i> , 2020, 276, 570-575.	2.0	30

#	ARTICLE	IF	CITATIONS
19	The emerging role of psilocybin and MDMA in the treatment of mental illness. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1263-1273.	1.4	29
20	The Association Between Adverse Childhood Experiences and Inflammation in Patients with Major Depressive Disorder: A Systematic Review. <i>Journal of Affective Disorders</i> , 2020, 272, 1-7.	2.0	28
21	Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review. <i>Journal of Affective Disorders</i> , 2021, 293, 285-294.	2.0	28
22	Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review. <i>Journal of Psychiatric Research</i> , 2021, 137, 426-436.	1.5	27
23	The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review. <i>Journal of Psychiatric Research</i> , 2021, 137, 232-241.	1.5	25
24	Development and implementation of guidelines for the management of depression: a systematic review. <i>Bulletin of the World Health Organization</i> , 2020, 98, 683-697H.	1.5	25
25	A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions. <i>Journal of Affective Disorders</i> , 2021, 282, 160-164.	2.0	24
26	Registered clinical trials investigating ketamine for psychiatric disorders. <i>Journal of Psychiatric Research</i> , 2020, 127, 1-12.	1.5	22
27	Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression. <i>Advances in Therapy</i> , 2021, 38, 2795-2820.	1.3	19
28	The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE). <i>Psychiatry Research</i> , 2021, 302, 113993.	1.7	16
29	Ecological momentary assessment of depressive symptoms using the mind.me application: Convergence with the Patient Health Questionnaire-9 (PHQ-9). <i>Journal of Psychiatric Research</i> , 2021, 135, 311-317.	1.5	15
30	Mental, emotional, and behavioral effects of ketogenic diet for non-epileptic neuropsychiatric conditions. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 102, 109947.	2.5	14
31	Immune response to vaccination in adults with mental disorders: A systematic review. <i>Journal of Affective Disorders</i> , 2022, 304, 66-77.	2.0	14
32	The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Psychopharmacology</i> , 2021, 35, 128-136.	2.0	11
33	The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine. <i>Journal of Affective Disorders</i> , 2021, 294, 592-596.	2.0	10
34	Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorder. <i>Journal of Affective Disorders</i> , 2021, 282, 448-453.	2.0	9
35	The impact of overweight/obesity on monetary reward processing: A systematic review. <i>Journal of Psychiatric Research</i> , 2021, 137, 456-464.	1.5	9
36	The Prevalence of Suicidal Behaviour in Fibromyalgia Patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 108, 110078.	2.5	7

#	ARTICLE	IF	CITATIONS
37	Loneliness-based impaired reward system pathway: Theoretical and clinical analysis and application. <i>Psychiatry Research</i> , 2021, 298, 113800.	1.7	7
38	Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 104, 110032.	2.5	6
39	Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?. <i>Journal of Affective Disorders</i> , 2021, 292, 714-719.	2.0	5
40	Frequency Analysis of Symptomatic Worsening Following Ketamine Infusions For Treatment Resistant Depression in a Real-World Sample: Results From the Canadian Rapid Treatment Centre of Excellence. <i>Psychiatry Research</i> , 2021, 307, 114321.	1.7	5
41	Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence. <i>Journal of Psychiatric Research</i> , 2021, 143, 209-214.	1.5	3
42	The effects of antidepressant medications on antiretroviral treatment adherence in HIV-positive individuals with depression. <i>Journal of Affective Disorders</i> , 2022, 300, 219-225.	2.0	3
43	Inflammation and disease modification in bipolar disorders: Priority avenues for future research. <i>Bipolar Disorders</i> , 2021, 23, 442-444.	1.1	2
44	The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies. <i>Psychiatry Research</i> , 2022, 313, 114577.	1.7	2